Rethinking Targeted Therapy in Bullous Pemphigoid

For years, bullous pemphigoid (BP) management has relied heavily on broad immunosuppressive approaches—often effective but frequently limited by long-term safety and tolerability concerns. As our understanding of BP pathophysiology has evolved, so has the therapeutic landscape. This experience explores a targeted treatment approach designed to address key drivers of type 2 inflammation implicated in BP, offering clinicians a closer look at how biologic therapy is shaping care for adult patients today.

Early Treatment of HS With Secukinumab

Sekukinumab Long-Term Phase 3 Data

Pooled Phase 3 Data From CSU Trials

CSU Disease Activity Data From a Phase 3 Trial